The FLT3 gene encodes a receptor tyrosine kinase that regulates cell survival, proliferation, and differentiation. Mutations such as internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations (D835Y) disrupt this pathway, leading to uncontrolled leukemic cell growth. Present in 20–30% of acute myeloid leukemia (AML) patients, FLT3 mutations are among the most critical genetic abnormalities influencing disease progression, treatment selection, and prognosis. Identifying these mutations is crucial for risk stratification in AML, as patients with these alterations often experience aggressive disease but may respond well to FLT3-targeted therapies.
To address this important clinical need, Genes2Me introduces the FLT3-Q Real-Time PCR Kit — an advanced in vitro diagnostic solution designed for the detection of FLT3-ITD (via gel-based electrophoresis) and FLT3-TKD mutations D835–I836 (via real-time PCR). Combining highly sensitive Real-Time PCR with confirmatory gel-based analysis, this kit enables timely and precise mutation detection to support personalised treatment decisions and improved outcomes in AML.
The FLT3-Q Kit employs a dual-methodology approach to ensure comprehensive and robust mutation detection. FLT3-ITD mutations are identified via gel-based electrophoresis, while FLT3-TKD mutations (D835–I836) are detected using Real-Time PCR with TaqMan probe chemistry. A HEX-labeled internal control probe validates sample integrity and PCR workflow in every run, minimising the risk of false-negative results. This combined qPCR and gel-based workflow enhances the overall robustness of results and delivers reproducible, clinically actionable mutation data within hours.
FLT3 mutation testing is an indispensable tool in AML diagnosis and management. With the rise of FLT3 inhibitors as standard-of-care therapies, accurate detection of FLT3-ITD and FLT3-TKD mutations provides oncologists and haematologists with actionable genetic insights that directly influence treatment pathways and therapy selection. By detecting mutations at Ct ≤ 35, the FLT3-Q Kit delivers reliable performance that supports risk stratification, guides personalised treatment strategies, and contributes to improved survival rates in AML patients.
Accurately identifies both FLT3-ITD (via gel-based electrophoresis) and FLT3-TKD D835–I836 mutations (via real-time PCR) in a single kit.
Detects mutations with Ct ≤ 35, ensuring confidence in diagnostic reporting across diverse clinical samples.
HEX-labeled internal control probe validates sample integrity and PCR workflow in every run, minimising false-negative results.
Combines quantitative PCR with confirmatory gel-based electrophoresis analysis, enhancing the robustness and reliability of results.
Validated on leading Real-Time PCR platforms including Thermo Fisher QuantStudio™ 5, Bio-Rad CFX96, Roche LightCycler® 480, and Genes2Me RapiCycler 96.
Delivers reproducible results within hours, supporting timely clinical decision-making in AML management.
With the FLT3-Q Real-Time PCR Kit, laboratories can achieve highly sensitive, reproducible, and clinically meaningful detection of FLT3-ITD and FLT3-TKD mutations. By supporting risk stratification, targeted therapy selection, and improved clinical evaluation of AML, the kit helps clinicians make informed decisions for patient care and disease management. Empower your laboratory with the FLT3-Q Real-Time PCR Kit — because timely molecular insights can make a lasting difference in patient outcomes.
When the Ct value of the sample to be tested is outside the reference range and there is a typical S-shaped amplification curve, the test result is positive; When the Ct value of the sample to be tested is within the reference range, or the Ct value is outside the reference range but there is no typical S-shaped amplification curve, the test result is negative.
Channel 1 Slope: -3.392 Intercept: 39.372 Correlation: -0.998 Efficiency 3: 97.1430 Channel 3 Slope: -3.240 Intercept: 38.672 Correlation: -0.999 Efficiency 2: 103.52
| Commercial Name | Old Cat No. | New Cat No. | Pack Size |
|---|---|---|---|
| FLT3-Q Real-Time PCR Kit | G2M709021 | G610025-1 | 50 Tests |
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
© 2025 Genes2me. All rights reserved.
